DelveInsight’s, “Anaplastic Astrocytoma Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Anaplastic Astrocytoma pipeline landscape. It covers the Anaplastic Astrocytoma pipeline drug profiles, including Anaplastic Astrocytoma clinical trials and nonclinical stage products. It also covers the Anaplastic Astrocytoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Anaplastic Astrocytoma Emerging drugs, the Anaplastic Astrocytoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Anaplastic Astrocytoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Anaplastic Astrocytoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Anaplastic Astrocytoma clinical trials studies, Anaplastic Astrocytoma NDA approvals (if any), and product development activities comprising the technology, Anaplastic Astrocytoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Anaplastic Astrocytoma Pipeline Report
To explore more information on the latest breakthroughs in the Me Anaplastic Astrocytoma Pipeline treatment landscape of the report, click here @ Anaplastic Astrocytoma Pipeline Outlook
Anaplastic Astrocytoma Overview
Anaplastic Astrocytoma is a rare malignant brain tumor. Astrocytomas are tumors that develop from certain star-shaped brain cells called astrocytes. Astrocytes and similar cells form tissue that surrounds and protects other nerve cells found within the brain and spinal cord. Collectively, these cells are known as glial cells and the tissue they form is known as glial tissue. Tumors that arise from glial tissue, including astrocytomas, are collectively referred to as gliomas. The symptoms of Anaplastic Astrocytomas vary depending upon the specific location and size of the tumor. The specific cause of this tumor is unknown.
Recent Developmental Activities in the Anaplastic Astrocytoma Treatment Landscape
For further information, refer to the detailed Anaplastic Astrocytoma Unmet Needs, Anaplastic Astrocytoma Market Drivers, and Anaplastic Astrocytoma Market Barriers, click here for Anaplastic Astrocytoma Ongoing Clinical Trial Analysis
Anaplastic Astrocytoma Emerging Drugs Profile
Eflornithine, also known as α-diflurormethylornithine (DFMO), selectively targets and irreversibly inhibits ornithine decarboxylase (ODC), an enzyme essential for polyamine synthesis, and DNA and RNA function. Unlike multi-targeted tyrosine kinase inhibitors on the market or in development, eflornithine targets only one specific enzyme, ODC. In animal studies, eflornithine has been shown to inhibit the growth of malignant tumors, including intra cerebral mid- and high-grade gliomas. Eflornithine administration has also been shown to potentiate the anti-tumor activity of other chemotherapy agents. In single-arm and controlled, randomized clinical trials, eflornithine oral solution increased survival in patients with both newly diagnosed and recurrent anaplastic glioma. The primary and reversible side effects of eflornithine were diarrhea and hearing impairment.
Zotiraciclib is a potent oral spectrum selective kinase inhibitor for the treatment of cancer. It was discovered in Singapore by S*BIO Pte Ltd and falls under the category of small molecule macrocycles. It crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9. In October 2021, Cothera Bioscience Inc. and Adastra Pharmaceuticals Inc., announced a definitive agreement under which Cothera has acquired zotiraciclib (ZTR).
Anaplastic Astrocytoma Pipeline Therapeutics Assessment
There are approx. 15+ key companies which are developing the therapies for Anaplastic Astrocytoma. The companies which have their Anaplastic Astrocytoma drug candidates in the most advanced stage, i.e. phase III include, Orbus Therapeutics.
Request a sample and discover the recent advances in Anaplastic Astrocytoma Ongoing Clinical Trial Analysis and Medications, click here @ Anaplastic Astrocytoma Treatment Landscape
Scope of the Anaplastic Astrocytoma Pipeline Report
Dive deep into rich insights for drugs for Anaplastic Astrocytoma Market Drivers and Anaplastic Astrocytoma Market Barriers, click here @ Anaplastic Astrocytoma Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Anaplastic Astrocytoma Mergers and acquisitions, Anaplastic Astrocytoma Licensing Activities @ Anaplastic Astrocytoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
